Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
Earnings Data
Report Date
May 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.79Last Year’s EPS
-1.22Same Quarter Last Year
Strong Buy
Based on 17 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and robust pipeline progress: substantial year-over-year revenue growth (+65% Q4, +66% full year), breakout performance of Auvelity (surpassing $500M annual sales in year three), multiple upcoming clinical readouts and regulatory milestones (Auvelity sNDA priority review, imminent AXS-12 NDA, several Phase III starts), and strategic in-licensing (AXS-17). Offsetting factors include expanding gross-to-net discounts (pressuring net realizations), a sizable increase in SG&A to fund commercialization and DTC, modest early Cymbravo sales with high launch discounts, and some clinical enrollment timing delays. Overall, the positives (strong top-line growth, product momentum, regulatory progress and pipeline breadth) materially outweigh the challenges, leading to a constructive outlook.Company Guidance
Strong Top-Line Revenue Growth
Total product revenue of $196,000,000 in Q4 2025, up 65% year-over-year; full year 2025 revenue of $638.5 million, up 66% year-over-year.
Auvelity Rapid Commercial Success
Auvelity net product sales of $155.1 million in Q4 2025 (up 68% YoY) and $507.1 million for the full year (up 74% YoY), surpassing $500 million in its third full year from launch; >225,000 prescriptions in the quarter (+42% YoY, +8% sequential) and ~52,000 unique prescribers since launch.
Sunosi Continued Growth
Sunosi net product revenue of $36.7 million in Q4 2025, up 40% YoY, and $124.8 million for the full year (up 32% YoY); >54,000 prescriptions in the quarter (+11% YoY, +3% sequential) and ~15,100 cumulative prescribers.
Cymbravo Early Launch Momentum
Cymbravo generated $4.1 million in Q4 net sales and $6.6 million for the full year following its second full quarter of launch; >13,000 total prescriptions with ~5,300 new patients started in the quarter and contracting with a third large commercial GPO to enable negotiations with major payers.
Pipeline Advancement and Regulatory Milestone
sNDA for Auvelity in Alzheimer's disease agitation accepted with Priority Review and PDUFA action date of April 30, 2026; launch readiness underway. Multiple pipeline moves: imminent NDA submission for AXS-12 (narcolepsy), Phase III initiation plans for AXS-05 (smoking cessation) in Q2, Phase III starts/updates for solriamfetol across ADHD, binge eating disorder (ENGAGE topline expected H2 2026), MDD with EDS (startup this quarter), and AXS-14 Phase III FORWARD initiated in fibromyalgia.
Strategic Acquisition and New Program
In-licensed AZD7325 (now AXS-17) with favorable safety in >700 patients to date; planning Phase II-enabling activities targeting epilepsy based on compelling preclinical seizure-model data.
Improved Profitability Trends and Cash Position
Q4 2025 net loss narrowed to $28.6 million ($0.56/sh) vs. $74.9 million in Q4 2024; full year net loss improved to $183.2 million ($3.68/sh) from $287.2 million in 2024. Cash and equivalents of $323.0 million at year-end (vs. $315.0 million prior year) and management expects cash sufficient to fund operations into cash-flow positivity under the current plan.
Commercial Infrastructure Scaling
Sales force expansion underway to ~600 representatives (from ~300) to support MDD growth and potential Alzheimer's agitation launch; DTC campaign produced new patient starts inflection with optimization planned for 2026.
AXSM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AXSM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 23, 2026 | $183.72 | $174.76 | -4.88% |
Nov 03, 2025 | $134.99 | $135.75 | +0.56% |
Aug 04, 2025 | $103.02 | $106.54 | +3.42% |
May 05, 2025 | $112.21 | $116.49 | +3.81% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Axsome Therapeutics Inc (AXSM) report earnings?
Axsome Therapeutics Inc (AXSM) is schdueled to report earning on May 11, 2026, Before Open (Confirmed).
What is Axsome Therapeutics Inc (AXSM) earnings time?
Axsome Therapeutics Inc (AXSM) earnings time is at May 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AXSM EPS forecast?
AXSM EPS forecast for the fiscal quarter 2026 (Q1) is -0.79.